The Centers for Medicare and Medicaid Services plans to terminate four demonstration projects by the end of 2025, closing out ...

Alkem Laboratories has launched a generic medication for type-2 diabetes, chronic kidney disease and heart failure in India ...

Zydus Lifesciences has received USFDA approval to manufacture its generic version of Methenamine Hippurate tablets for ...

A study found Indian generics sold in the US between 2009-2018 linked to a 54% higher risk of serious side effects compared ...

Generic versions of diabetes drug Empagliflozin launched in India, crashing prices by 80-90% on day one post-patent expiry.

Four companies have applied to Health Canada to sell copies of Ozempic after its market exclusivity expires on Jan. 4, 2026 ...

Mankind Pharma, Alkem Laboratories, Glenmark are some of the companies to have launched, making the drug affordable to most ...

Glenmark and Alkem Labs launched the generic version as well as its Fixed Dose Combination (FDCs) of Empagliflozin in India.

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...

Mankind Pharma and other domestic companies have launched generic versions of the popular diabetes drug Empagliflozin at ...

The acquired portfolio consists of 13 ANDAs already approved by the Food and Drug Administration and one pending approval.

Sirolimus, the active ingredient in Felycin-CA1, at a higher dose is used as an immunosuppressant in human patients receiving ...